{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T20:58:39Z","timestamp":1765832319914,"version":"3.48.0"},"reference-count":24,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100006090","name":"Center for Global Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,11,19]]},"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterise the costs, including for environmental surveillance (ES), of the Global Polio Laboratory Network (GPLN) that provides laboratory support to the Global Polio Eradication Initiative (GPEI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and participants<\/jats:title>\n                    <jats:p>We conducted a survey of the network across 92 countries of the 146 GPLN laboratories plus three non-GPLN laboratories that concentrate environmental samples to collect information about their activities, characteristics and costs during 2016. We estimate the total costs using regression of reported responses and complementing the findings with GPEI data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We received responses from 132 (89%) of the 149 laboratories, with variable response rates for individual questions. We estimate that processing samples of patients with acute flaccid paralysis leads to total costs of approximately $28\u2009million per year (2016 US$) based on extrapolation from reported costs of $16\u2009million, of which 61% were supported by internal (national) funds. Fifty-nine (45%) of the 132 responding laboratories reported supporting ES and we estimate an additional $5.3\u2009million of recurring costs for ES activities performed by the laboratories. The reported costs do not include an estimated additional $10\u2009million of annual global and regional costs to coordinate and support the GPLN. On average, the staff supported by funding for polio in the responding laboratories spent 30% of their time on non-polio activities. We estimate total costs for laboratory support of approximately $43\u2009million (note that this estimate does not include any field or other non-laboratory costs of polio surveillance).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although countries contribute significantly to the GPLN financing, many laboratories currently depend on GPEI funds, and these laboratories also support the laboratory component of surveillance activities for other diseases. Sustaining critical global surveillance for polioviruses and transitioning support for other disease programmes will require continued significant funding after polio certification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-023290","type":"journal-article","created":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T09:36:54Z","timestamp":1548149814000},"page":"e023290","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Characterising the costs of the Global Polio Laboratory Network: a survey-based analysis"],"prefix":"10.1136","volume":"9","author":[{"given":"Radboud J","family":"Duintjer Tebbens","sequence":"first","affiliation":[{"name":"Kid Risk, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ousmane M","family":"Diop","sequence":"additional","affiliation":[{"name":"Global Polio Eradication Initiative, World Health Organization, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A","family":"Pallansch","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Steven","family":"Oberste","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly M","family":"Thompson","sequence":"additional","affiliation":[{"name":"Kid Risk, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,1,21]]},"reference":[{"key":"2025121512532319000_9.1.e023290.1","unstructured":"World Health Assembly. Global eradication of poliomyelitis by the year 2000 (resolution 41.28). Geneva: World Health Organization, 1988."},{"key":"2025121512532319000_9.1.e023290.2","unstructured":"Global Polio Eradication Initiative. Strategy. 2017 http:\/\/polioeradication.org\/ (accessed 14 Dec 2017)."},{"key":"2025121512532319000_9.1.e023290.3","unstructured":"Global Polio Eradication Initiative. Global eradication of wild poliovirus type 2 declared 2015. 2015. [updated 20 Sep 2015]. http:\/\/www.polioeradication.org\/mediaroom\/newsstories\/Global-eradication-of-wild-poliovirus-type-2-declared\/tabid\/526\/news\/1289\/Default.aspx (accessed 30 Nov 2015)."},{"key":"2025121512532319000_9.1.e023290.4","first-page":"1031","article-title":"Possible eradication of wild poliovirus type 3-worldwide, 2012","volume":"63","author":"Kew","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025121512532319000_9.1.e023290.5","unstructured":"\u00a0World Health Organization. Global Polio Eradication Initiative: Polio Eradication and Endgame Strategic Plan (2013-2018). Geneva 2013."},{"key":"2025121512532319000_9.1.e023290.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1539-6924.2006.00827.x"},{"key":"2025121512532319000_9.1.e023290.7","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6535a3"},{"key":"2025121512532319000_9.1.e023290.8","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6620a4"},{"key":"2025121512532319000_9.1.e023290.9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12879-015-1112-8","article-title":"An economic analysis of poliovirus risk management policy options for 2013-2052","volume":"15","author":"Duintjer Tebbens","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2025121512532319000_9.1.e023290.10","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6643a6"},{"key":"2025121512532319000_9.1.e023290.11","doi-asserted-by":"crossref","unstructured":"Duizer E , Ruijs WL , van der Weijden CP , et al . Response to a wild poliovirus type 2 (WPV2)-shedding event following accidental exposure to WPV2, the Netherlands, April 2017. Euro Surveill 2017;22.doi:10.2807\/1560-7917.ES.2017.22.21.30542","DOI":"10.2807\/1560-7917.ES.2017.22.21.30542"},{"key":"2025121512532319000_9.1.e023290.12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12879-015-1115-5","article-title":"Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs","volume":"15","author":"Duintjer Tebbens","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2025121512532319000_9.1.e023290.13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005114"},{"key":"2025121512532319000_9.1.e023290.14","unstructured":"\u00a0Global Polio Eradication Initiative. GPEI Budget 2017 2017. updated 1 Jun 2017. http:\/\/polioeradication.org\/financing\/financial-needs\/financial-resource-requirements-frr\/gpei-budget-2017\/ (accessed 14 Dec 2017)."},{"key":"2025121512532319000_9.1.e023290.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1539-6924.2006.00845.x"},{"key":"2025121512532319000_9.1.e023290.16","unstructured":"\u00a0Global Polio Eradication Initiative. Guidelines on environmental surveillance for detection of polioviruses - working draft - March 2015, 2015."},{"key":"2025121512532319000_9.1.e023290.17","unstructured":"\u00a0World Health Organization. Guidelines for environmental surveillance of poliovirus circulation. Geneva: Department of Vaccines & Biologicals, WHO, 2003."},{"key":"2025121512532319000_9.1.e023290.18","unstructured":"\u00a0XE.com. Current and historical rate tables. 2017 http:\/\/www.xe.com\/currencytables\/?from=USD&date=2016-07-01 (accessed 15 Nov 2017)."},{"key":"2025121512532319000_9.1.e023290.19","unstructured":"\u00a0World Bank. World Bank analytical classifications - calendar year 2016 GNI per capita in US$ (Atlas methodology). 2017 http:\/\/databank.worldbank.org\/data\/download\/site-content\/OGHIST.xls (accessed 13 Dec 2017)."},{"key":"2025121512532319000_9.1.e023290.20","doi-asserted-by":"publisher","DOI":"10.1017\/S095026881000316X"},{"key":"2025121512532319000_9.1.e023290.21","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1537-8"},{"key":"2025121512532319000_9.1.e023290.22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12879-016-1465-7","article-title":"Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame","volume":"16","author":"Duintjer Tebbens","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2025121512532319000_9.1.e023290.23","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12560-017-9314-4","article-title":"Insights from a systematic search for information on designs, costs, and effectiveness of poliovirus environmental surveillance systems","volume":"9","author":"Duintjer Tebbens","year":"2017","journal-title":"Food Environ Virol"},{"key":"2025121512532319000_9.1.e023290.24","doi-asserted-by":"crossref","first-page":"S287","DOI":"10.1093\/infdis\/jix026","article-title":"Transition planning for after polio eradication","volume":"216","author":"Rutter","year":"2017","journal-title":"J Infect Dis"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-023290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T20:53:30Z","timestamp":1765832010000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-023290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,21]]},"published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1136\/bmjopen-2018-023290"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-023290","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}